261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis

Client Name: Northern Craft Cannabis
License Number: WHSL0003

Sample ID: 20260923-36955
Sample Name: 1g Berries and Cream Vape Cart
Sample Lot: MANU0035-26-NCC-BCO2-VAPE-01
Sample Matrix: Solvent Extraction Concentrates
Date Received: 9/24/2026
Date Reported: 10/1/2026
Date Tested: 9/29/2026



Total Terpenes (%) : 3.0682

Dominant Terpenes (%)	
beta-caryophyllene	**0.7214**
Myrcene	**0.4155**
Limonene	**0.3981**
Linalool	**0.3865**
alpha-Humulene	**0.2694**

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-020-OA) | **Test ID: #121794**

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.2614	2.614	0.000003	0.001
alpha-Humulene	0.2694	2.694	0.000002	0.001
alpha-Pinene	0.155	1.55	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	0.0861	0.861	0.000004	0.001
beta-caryophyllene	0.7214	7.214	0.000004	0.001
beta-Pinene	0.0463	0.463	0.000002	0.001
Camphene	0.0226	0.226	0.000001	0.001
Caryophyllene Oxide	0.0655	0.655	0.000011	0.001
Eucalyptol	ND	ND	0.000002	0.001
gamma-Terpinene	ND	ND	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	0.168	1.68	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.3981	3.981	0.000002	0.001
Linalool	0.3865	3.865	0.000003	0.001
Nerolidol	0.0527	0.527	0.000007	0.001
Myrcene	0.4155	4.155	0.000003	0.001
Ocimene	0.0197	0.197	0.000002	0.001
Total Terpenes	**3.0682**	**30.682**		

Callie Chapman
Lab Director
10/1/2026

Rev. 1	Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; (e) OA does not utilize decision rules, results are reported as simple acceptance. MOU is not taken into account for statements of conformity (e.g. regulatory action limits "pass/fail"); and (f) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.